Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-20T00:47:51.414Z Has data issue: false hasContentIssue false
  • English
  • Français

Cough Syrup Psychosis

Published online by Cambridge University Press:  11 May 2015

Alfred Amaladoss  and
Simon O'Brien
Alfred Amaladoss*
Affiliation:
Department of Psychiatry, Queen's University, Kingston, ON
Simon O'Brien
Affiliation:
Department of Psychiatry, Queen's University, Kingston, ON
*
Department of Psychiatry, Queen's University, Kingston, ON, K7L5G2; [email protected]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Over-the-counter medications are widely accessible and used. Cough suppressant syrups contain dextromethorphan (DM), which has the potential to be abused, with resultant psychiatric symptoms. This case report describes a young woman presenting with psychotic mania secondary to DM abuse. We also describe the treatment of this toxidrome and include the results of a literature search on this topic. The recognition of cough syrup as an agent of abuse and its toxidrome is important. This will facilitate early diagnostic clarification and promote efficient treatment strategies.

Keywords

cough syrupdextromethorphanpsychosissubstance abuse
Type
Case Report • Rapport de cas
Information
Canadian Journal of Emergency Medicine , Volume 13 , Issue 1 , January 2011 , pp. 53 - 56
Copyright
Copyright © Canadian Association of Emergency Physicians 2011

References

REFERENCES

1.Bem, JL, Peck, R. Dextromethorphan. An overview of safety issues. Drug Saf 1992;3:190–9.CrossRefGoogle Scholar
2.Miller, SC. Dextromethorphan psychosis, dependence and physical withdrawal. Addict Biol 2005;10:325–7.CrossRefGoogle ScholarPubMed
3.The Vaults of Erowid. Available at: http://www.erowid.org/ (accessed October, 2010).Google Scholar
4.Swartz, RH. Adolescent abuse of dextromethorphan. Clin Pediatr (Phila) 2005;45:565–8.CrossRefGoogle Scholar
5.Franklin, PH, Murray, TF. High affinity[H3] dextrorphan binding in rat brain is localized to a noncompetitive antagonist site of the activated N-methyl-D-aspartate receptor-cation channel. Mol Pharmacol 1992;41:134–46.Google ScholarPubMed
6.Whittemore, ER, Ilyin, VI, Woodward, RM. Antagonism of N-methyl-D-aspartate receptors by [sigma] site ligands: potency, subtype-selectively and mechanism of inhibition. J Pharmacol Exp Ther 1997;282:326–38.Google Scholar
7.Gonzalez, GM, Werling, LL. Release of [3H]dopamine from guinea pig striatal slices is modulated by sigma 1 receptor agonists. Naunyn ScmiedebergsArch Pharmacol 1997;356:455–61.Google Scholar
8.Yamamoto, H, Yamamoto, T, Sagi, N, et al. Sigma ligands indirectly modulate the NMDA receptor-ion channel complex on intact neuronal cells via sigma 1 site. J Neurosci 1995;15:731–6.Google Scholar
9.Meoni, P, Tortella, FC, Bowery, NG. An autoradiographic study of dextromethorphan high-affinity binding sites in rat brain: sodium-dependency and colocalization with paroxetine. Br J Pharmacol 1997;120:1255–62.CrossRefGoogle ScholarPubMed
10.Schadel, M, Sellers, E. Psychosis with Vicks Formula 44D. Can Med Assoc J 1992;147:843–4.Google ScholarPubMed
11.Dickerson, DL, Schaepper, MA, Peterson, MD, et al. Coricidin HBP abuse: patient characteristics and psychiatric manifestations as recorded in an inpatient psychiatric unit. J Addict Dis 2008;1:25–32.CrossRefGoogle Scholar
12.Price, LH, Lebel, J. Dextromethorphan-induced psychosis. Am J Psychiatry 2000;157:304.Google Scholar